SCHEMBL8006836

SCHEMBL8006836

COc1cc(N)c(O)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.67
GAA P10253 3/20 0.61
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
MCL1 Q07820 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HSP90AA1 P07900 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2793205 0.92 GAA (0.67) NPC1GAAALDH1A1SMN1; SMN2HPGD
SCHEMBL27037781 0.82 KDM4E (0.50) NPC1GAAALDH1A1SMN1; SMN2HSD17B10
SCHEMBL5951825 0.82 GAA (0.78) NPC1GAAALDH1A1MAPK1HSD17B10
SCHEMBL29466462 0.80 GAA (0.83) NPC1GAAALDH1A1MAPK1HSD17B10
SCHEMBL29601238 0.80 NPC1 (1.00) NPC1GAAALDH1A1SMN1; SMN2HSD17B10
SCHEMBL11548272 0.80 TSHR (0.52) NPC1GAAALDH1A1SMN1; SMN2HPGD
SCHEMBL4398163 0.80 GAA (0.56) NPC1GAAALDH1A1HPGDHSD17B10
SCHEMBL29950205 0.80 PKM (0.53) NPC1GAAALDH1A1SMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL1401287 0.80 GAA (0.75) NPC1GAAALDH1A1MAPK1HSD17B10
SCHEMBL92067 0.80 GAA (0.83) NPC1GAAALDH1A1MAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
US-20190194179-A1 ANTIBIOTIC COMPOUNDS DISCUVA LTD. (GB) 2019-06-27 US disclosed
US-20190194179-A1 ANTIBIOTIC COMPOUNDS DISCUVA LTD. (GB) 2019-06-27 US disclosed
EP-0648816-B1 Dyeing of leather with dyestuff mixtures CIBA SC HOLDING AG (CH) 2000-01-26 EP disclosed
EP-0648816-A1 Dyeing of leather with dyestuff mixtures CIBA-GEIGY AG (CH) 1995-04-19 EP disclosed
EP-0061670-B2 Process for dyeing leather and pelts with dye mixtures CIBA GEIGY AG (CH) 1994-06-01 EP disclosed
US-5204453-A Process for the preparation of 1:2 metal complex azo compounds by carrying out diazotization and coupling in the presence of a metal donor CIBA-GEIGY CORPORATION (US) 1993-04-20 US disclosed
EP-0278910-B1 HEAVY METAL COMPLEX DYESTUFFS, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1992-01-22 EP disclosed
US-4085097-A Process for the manufacture of chromium complexes from metallizable azo or azo methine dyes CIBA-GEIGY AG (CH) 1978-04-18 US disclosed
US-RE29585-E DYEING WOOL CIBA-GEIGY CORPORATION (US) 1978-03-21 US disclosed
US-4067864-A FOR CELLULOSE OR POLYAMIDES CIBA-GEIGY AG (CH) 1978-01-10 US disclosed
US-4039523-A YELLOW CIBA-GEIGY AG (CH) 1977-08-02 US disclosed
US-4033942-A Chromium complex dye, including azo and azo methine dye compounds CIBA-GEIGY AG (CH) 1977-07-05 US disclosed
US-4017477-A 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs CIBA-GEIGY AG (CH) 1977-04-12 US disclosed
US-4005067-A Process for the synthesis of nitrite ion-containing 1:1 complexes of cobalt and metallizable monoazo or azomethine compounds and such complexes SANDOZ LTD. (CH) 1977-01-25 US disclosed
US-3978037-A POLYAMIDES CIBA-GEIGY CORPORATION (US) 1976-08-31 US disclosed
US-3971738-A Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component CIBA-GEIGY AG (CH) 1976-07-27 US disclosed
US-3941765-A Process for the manufacture of symmetric 1:2 chromium complexes of azo dyes CIBA-GEIGY AG (CH) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194179-A1 ANTIBIOTIC COMPOUNDS B3GNT2, RPN2, RPN1 NPC1 114/4885GAA 77/4885ALDH1A1 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.